Thursday 16 October, 2025
Objectives: Tuberculosis is an infectious disease that every year infects and kills millions of people worldwide [1]. The standard of care,…
Read moreAbstracts
PBPK/PD modeling and machine learning approaches to support the development of new drugs and regimens against tuberculosis.
Thursday 16 October, 2025
Objectives: Tuberculosis (TB) is a major global health problem that causes millions of new cases and deaths every year. Several…
Read moreA pooled pharmacokinetic analysis of piperacillin-tazobactam in different patient populations
Thursday 16 October, 2025
Objectives: Piperacillin-tazobactam is a β-lactam/β-lactamase inhibitor combination product used against severe infections in the intensive care unit setting[1]. However, pharmacokinetics…
Read moreApplication of Physiologically-Based Pharmacokinetics using Simcyp to predict the exposure to Valproic Acid in human milk and pediatrics
Thursday 16 October, 2025
Objectives: This work is part of the Innovative medicines initiative (IMI) research consortium and project ConcePTION, with the main goal…
Read moreOPTIMIZATION OF THE DOSAGE REGIMEN OF LONG-ACTING INJECTABLE ARIPIPRAZOLE THROUGH MONTE CARLO SIMULATIONS
Thursday 16 October, 2025
Introduction/Objectives: Aripiprazole is an atypical antipsychotic widely used in the treatment of schizophrenia, bipolar disorder, and major depressive disorder with…
Read morePhysiologically based pharmacokinetic modelling to investigate the impact of obesity on the pharmacokinetics of rilpivirine, efavirenz, and etravirine
Thursday 16 October, 2025
Introduction: Nowadays, obesity represents a major public health problem [1]. The number of people affected by this disease is rising…
Read moreRepository of model parameters for physiologically based pharmacokinetic modelling in obese validated against triazolam and caffeine observed data
Thursday 16 October, 2025
Introduction: Obesity is a chronic and relapsing disease commonly defined by a body mass index (BMI) ≥ 30 kg/m2. The…
Read moreCabotegravir pharmacokinetics after oral and intramuscular administration using physiologically based pharmacokinetic modelling
Thursday 16 October, 2025
Introduction: Combined antiretroviral treatments have transformed HIV infection into a chronic disease. However, the efficacy of antiretroviral treatments relies on…
Read moreOnset and disappearance of induction on CYP3A4 and UGT1A1 substrates using PBPK modelling
Thursday 16 October, 2025
Introduction: Contemporary antiretrovirals (ARVs) have a lower propensity to cause drug-drug interactions (DDIs), however they can be subject to DDIs…
Read moreApplication of Structural Identifiability Analysis and Parametrisation of a Linear Mixed Effects Mirabegron Model
Thursday 16 October, 2025
Objectives: The application of structural identifiability analysis of a mathematical model is an essential step in its development to ensure…
Read more